 RSV infections can develop into serious, life threatening conditions among immunocompromised patients. The objective of this study ADMA 001 is to evaluate the safety and efficacy of RI-001 for the prevention of lower respiratory tract infections in immunocompromised patients identified as being infected with RSV in the upper respiratory tract. 